Evolutionary Tree Capital Management LLC Sells 34,041 Shares of PROCEPT BioRobotics Corporation $PRCT

Evolutionary Tree Capital Management LLC lessened its stake in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 33.7% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 66,869 shares of the company’s stock after selling 34,041 shares during the period. PROCEPT BioRobotics comprises about 3.1% of Evolutionary Tree Capital Management LLC’s holdings, making the stock its 16th biggest position. Evolutionary Tree Capital Management LLC’s holdings in PROCEPT BioRobotics were worth $1,672,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd boosted its stake in PROCEPT BioRobotics by 436.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after acquiring an additional 746 shares during the last quarter. Center for Financial Planning Inc. purchased a new stake in shares of PROCEPT BioRobotics during the 4th quarter worth approximately $40,000. US Bancorp DE increased its stake in shares of PROCEPT BioRobotics by 175.7% during the 3rd quarter. US Bancorp DE now owns 1,693 shares of the company’s stock worth $60,000 after purchasing an additional 1,079 shares during the last quarter. Cache Advisors LLC bought a new stake in shares of PROCEPT BioRobotics in the 1st quarter worth approximately $42,000. Finally, Lazard Asset Management LLC raised its holdings in shares of PROCEPT BioRobotics by 90.7% in the 2nd quarter. Lazard Asset Management LLC now owns 1,703 shares of the company’s stock worth $98,000 after purchasing an additional 810 shares during the period. Institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics News Roundup

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Investors who purchased PROCEPT shares between February 28, 2024, and February 25, 2026, have until September 22, 2026, to seek appointment as lead plaintiff in the pending class action. The notices are procedural and do not represent a court finding of wrongdoing. Deadline Alert: Procept BioRobotics Corporation Shareholders
• Negative Sentiment: The core allegations involve repeated underperformance in unit and handpiece sales, late-quarter bulk discounts, excess customer inventory, and sales being pulled forward. Plaintiffs allege these practices may have inflated recurring-revenue metrics and that the risks were not adequately disclosed. PROCEPT Faces Securities Class Action Amid Sales Pull-In Concerns
• Negative Sentiment: The unusually high volume of nearly identical law-firm announcements increases the visibility of the litigation and could weigh on the stock through potential legal costs, reputational damage, and uncertainty regarding the sustainability of demand and future revenue growth. PROCEPT Securities Fraud Class Action and Inventory Issues
• Negative Sentiment: UBS reportedly lowered its rating on PRCT to “Neutral,” adding to the cautious backdrop surrounding the company and its sales outlook. PROCEPT Rating Lowered to Neutral at UBS

PROCEPT BioRobotics Stock Performance

NASDAQ PRCT opened at $18.62 on Friday. The firm has a market cap of $1.06 billion, a P/E ratio of -10.23 and a beta of 0.87. The company has a quick ratio of 5.51, a current ratio of 6.73 and a debt-to-equity ratio of 0.15. The company’s 50 day moving average is $22.39 and its 200-day moving average is $25.19. PROCEPT BioRobotics Corporation has a 12-month low of $16.67 and a 12-month high of $51.38.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings data on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 27.70% and a negative net margin of 31.82%.The business had revenue of $83.13 million during the quarter, compared to the consensus estimate of $80.52 million. During the same period last year, the business posted ($0.45) earnings per share. The firm’s quarterly revenue was up 20.1% on a year-over-year basis. Sell-side analysts predict that PROCEPT BioRobotics Corporation will post -1.53 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on PRCT shares. Leerink Partners downgraded PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $31.00 to $29.00 in a research note on Thursday, June 11th. Truist Financial reissued a “hold” rating and issued a $25.00 target price (down from $30.00) on shares of PROCEPT BioRobotics in a research report on Thursday, July 2nd. Wall Street Zen upgraded PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. UBS Group cut PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 price target on the stock. in a research report on Tuesday. Finally, Citigroup downgraded PROCEPT BioRobotics to a “hold” rating in a research note on Thursday, July 2nd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, PROCEPT BioRobotics currently has an average rating of “Hold” and a consensus target price of $33.45.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.